Testing a new gene therapy approach for severe hemophilia A

This trial is testing BBM 002, an experimental gene therapy injection for hemophilia A—a bleeding disorder where the body doesn't make enough clotting factor VIII. The therapy uses a specially designed virus to carry instructions that help your body produce this clotting factor on its own. Researchers want to see if this treatment is safe and well-tolerated in people with severe hemophilia A.

People with severe hemophilia A currently need frequent injections or infusions of clotting factor to prevent dangerous bleeding. This medication aims to offer a longer-lasting solution by enabling the body to make its own clotting factor, potentially reducing or eliminating the need for regular infusions.